Teijin Limited (TYO:3401)
Japan · Delayed Price · Currency is JPY | Market Cap | 301.51B +38.8% |
| Revenue (ttm) | 909.24B -15.8% |
| Net Income | -81.60B |
| EPS | -423.25 |
| Shares Out | 192.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 50.00 (3.20%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 585,200 |
| Average Volume | 1,540,080 |
| Open | 1,566.50 |
| Previous Close | 1,574.50 |
| Day's Range | 1,545.50 - 1,574.00 |
| 52-Week Range | 1,095.00 - 1,747.00 |
| Beta | 0.29 |
| RSI | 41.66 |
| Earnings Date | May 11, 2026 |
About Teijin
Teijin Limited engages in the fibers, films and sheets, composites, healthcare, and IT businesses in Japan and internationally. The company provides aramid fibers; glass and carbon fibers, composite materials, infusion resins, adhesives, fillers and resin films, and oxidized PAN fibers; polycarbonate sheets and films; high-density polyethylene porous films and materials; and microporous films. It also offers PC resins, polyphenylene sulfide resins, molded parts, flame retardant, and additives; lightweight glass and carbon fiber reinforced compo... [Read more]
Financial Performance
In fiscal year 2025, Teijin's revenue was 1.01 trillion, a decrease of -2.64% compared to the previous year's 1.03 trillion. Earnings were 28.35 billion, an increase of 167.45%.
Financial StatementsNews
Automotive Aramid Fiber Market worth $1.30 billion by 2030, at a CAGR of 6.8%, says MarketsandMarkets™
Delray Beach, FL, April 24, 2026 (GLOBE NEWSWIRE) -- The Automotive Aramid Fiber Market is projected to grow from USD 0.94 billion in 2025 to USD 1.30 billion by 2030, at a CAGR of 6.8% during the for...
Teijin Earnings Call Transcript: Q3 2026
Q3 saw a decline in revenue and adjusted operating income, mainly due to business divestments and impairment losses, resulting in a net loss. The full-year outlook remains unchanged, with ongoing structural reforms and a focus on healthcare and fibers for future growth.
Teijin Transcript: Investor Day 2025
Customer-centric strategy leverages expertise in fibers, healthcare, and resin, focusing on high-value products and circular economy. Divestments and acquisitions sharpen core business, while new technologies and regional adaptation drive future growth.
Teijin Earnings Call Transcript: Q2 2026
Q2 FY2025 saw revenue and adjusted operating income decline year-over-year, mainly due to weakness in materials and aramid, while healthcare improved. FY2025 guidance was lowered, but the annual dividend is maintained. Cost reforms and restructuring are ongoing.
Teijin Earnings Call Transcript: Q4 2025
Fiscal 2024 saw profit growth, improved ROE, and strong Materials and Fibers & Products Converting performance. Fiscal 2025 is expected to bring higher adjusted operating income despite lower revenue from business divestitures, with continued focus on structural reforms and stable dividends.
Teijin Earnings Call Transcript: Q3 2025
Healthcare segment targets sustainable growth by leveraging its home care leadership, expanding into rare diseases, and integrating pharmaceuticals and devices, while mitigating pharma revenue risks from generics and price cuts.